| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2754918 | Clinical Lymphoma Myeloma and Leukemia | 2014 | 8 Pages |
Abstract
BuFlu is well tolerated and is less toxic than BuCy2 and our results did not suggest that in high-risk AML, BuCy2 should be the favorite regimen in terms of efficacy.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Roberta Fedele, Giuseppe Messina, Tiziana Martinello, Giuseppe Alberto Gallo, Antonella Pontari, Tiziana Moscato, Giuseppe Console, Antonia Dattola, Domenica Princi, Maria Cuzzola, Caterina Alati, Francesca Ronco, Stefano Molica, Giuseppe Irrera,